Chronic Lymphocytic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Lymphocytic Leukemia stocks.

Chronic Lymphocytic Leukemia Stocks Recent News

Date Stock Title
May 31 BIIB Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31 BIIB Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
May 31 BIIB Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
May 31 BIIB How To Invest: Using Shorter-Term Moving Averages To Trade Stocks
May 31 BIIB European Commission approves Biogen’s QALSODY for ALS treatment
May 30 BIIB EU approves Biogen treatment for genetic form of ALS
May 30 BIIB Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 30 TEVA Teva wins FDA nod for new Austedo formulation
May 30 TEVA FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea
May 29 TEVA Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
May 29 BIIB Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
May 29 BIIB Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN
May 29 AFMD Affimed gets FDA fast track status for AFM24 for EGFR lung cancer
May 29 AFMD Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
May 28 BIIB Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
May 28 AFMD Affimed Announces Annual General Meeting of Shareholders
May 27 BIIB South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s
May 27 BIIB The Biggest Biotechnology Company in Europe
Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

Browse All Tags